Salwa Akl



بسم الله الرحمن الرحيم

مركز الشبكات وتكنولوجيا المعلومات قسم التوثيق الإلكتروني



-Call +600-2

Salwa Akl



جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها على هذه الأقراص المدمجة قد أعدت دون أية تغيرات





Salwa Akl





بعض الوثائق الأصلية تالفة وبالرسالة صفحات لم ترد بالأصل



CD45 ISOFORM EXPRESSION ON PERIPHERAL BLOOD T-LYMPHOCYTES AMONG CHILDREN WITH SYSTEMIC LUPUS ERYTHEMATOSUS

Thesis

Submitted in partial fulfillment for the requirements of the M.Sc. Degrees of Pediatrics

NY MOHAMED BAG

Dr. MOHAMED FATHY MASOUD

M.B.B.Ch.

Supervised By

PROF. DR. ABD-EL RAHMMAN EL-SAADANY

Professor and Head of Pediatric Department

Benha Faculty of Medicine

Zagazig University

PROF. DR. SHÅHIN DABOUR

Ass. Prof. Of pediatrics Benha Faculty of Medicine Zagazig University PROF. DR. / MOHSEN EL-KAFRAWY

Ass. Prof. Of pediatrics Benha Faculty of Medicine Zagazig University

DR. SAFTA MOHAMMED DIAB

Lecturer of Clinical Pathology Benha Faculty of medicine Zagazig University

BENHA FACULTY OF MEDICINE
ZAGAZIG UNIVERSITY
1999

CD45 ISOFORM EXPRESSION ON PERIPHERAL BLOOD T-LYMPHOCYTES AMONG CHILDREN WITH SYSTEMIC LUPUS ERYTHEMATOSUS

Thesis

Submitted in partial fulfillment for the requirements of the M.Sc. Degrees of Pediatrics

NY MOHAMED BAG

Dr. MOHAMED FATHY MASOUD

M.B.B.Ch.

Supervised By

PROF. DR. ABD-EL RAHMMAN EL-SAADANY

Professor and Head of Pediatric Department

Benha Faculty of Medicine

Zagazig University

PROF. DR. SHÅHIN DABOUR

Ass. Prof. Of pediatrics Benha Faculty of Medicine Zagazig University PROF. DR. / MOHSEN EL-KAFRAWY

Ass. Prof. Of pediatrics Benha Faculty of Medicine Zagazig University

DR. SAFTA MOHAMMED DIAB

Lecturer of Clinical Pathology Benha Faculty of medicine Zagazig University

BENHA FACULTY OF MEDICINE
ZAGAZIG UNIVERSITY
1999

ACKNOWLEDGMENT

First 1 thank God, the most beneficent and merciful for the completion of this work.

I wish to express my deepest gratitude and greatest respect to Prof.Dr. Abd-El Rahmman El-Saadany, Professor and Head of Pediatric Department, Benha Faculty of Medicine, Zagazig University, for his enthusiastic encouragement, and supervision.

I would like to present my deepest gratitude to Assistant Prof.Dr. Mohsen El-Kafrawy, Ass.Prof. of pediatrics, Benha Faculty of Medicine, Zagazig University, for his valuable efforts of constructive guidance with which this work was possible.

I wish to express my thanks to Prof.Dr.Shahin Dabour ,Ass.Prof. of pediatrics, Benha Faculty of Medicine, Zagazig University, for his encouragement and valuable efforts to develop this study.

Words may fail to express my appreciation and sincere gratitude to Dr.Safiaa Mohamed Diab, Lecturer of Clinical Pathology, Benha Faculty of Medicine, Zagazig University for her generous help and valuable assistance.

Last but not least, I am greatly indebted to my Parents and wife for their loving, kindness and encouragement throughout this work which I dedicate to them.

ACKNOWLEDGMENT

First 1 thank God, the most beneficent and merciful for the completion of this work.

I wish to express my deepest gratitude and greatest respect to Prof.Dr. Abd-El Rahmman El-Saadany, Professor and Head of Pediatric Department, Benha Faculty of Medicine, Zagazig University, for his enthusiastic encouragement, and supervision.

I would like to present my deepest gratitude to Assistant Prof.Dr. Mohsen El-Kafrawy, Ass.Prof. of pediatrics, Benha Faculty of Medicine, Zagazig University, for his valuable efforts of constructive guidance with which this work was possible.

I wish to express my thanks to Prof.Dr.Shahin Dabour ,Ass.Prof. of pediatrics, Benha Faculty of Medicine, Zagazig University, for his encouragement and valuable efforts to develop this study.

Words may fail to express my appreciation and sincere gratitude to Dr.Safiaa Mohamed Diab, Lecturer of Clinical Pathology, Benha Faculty of Medicine, Zagazig University for her generous help and valuable assistance.

Last but not least, I am greatly indebted to my Parents and wife for their loving, kindness and encouragement throughout this work which I dedicate to them.

LIST OF ABBREVIATIONS

ANA Antinuclear antibody. Anti-ds Anti-double stranded. APC Antigen presenting cell. APL Anti phospholipid antibody. ARA American Rheumatic Association. BaEV. Babaon endogenous virus. BILAG British international lupus assesment group. CAMP Cyclic adenosin monophosphate. C 1,2,3,4 Complement 1,2,3,4. CD Cluster of differentation. **CCHB** Congenital complete heart block, CHB Complete heart block. C.N.S. Central nervous system. CTLs Cytosolic T-lymphocytes. DAG di-acyl glycerol DNA deoxy riboneuclic acid. DP Douple positive **EBV** Ebestien bar virus **EEG** Electro encephalogram. Enzyme linked immunosorbent assay. **ELLSA** ESR Erythrocyte sedimentation rate. Extractable nuclear antigen. ENA ET-1 Endothelin-1 FANA Fluorescent antinuclear antibody. **GIT** Gastro intestinal tract. Hb Hemoglobin. HIAb Human intercisternal type A retro virus particle. HERVS Human endogenous retro virus. HIV Human immune deficiency virus. Human leukocyte antigen. HLA HTL v-1 Human T-lymphotropic virus. ITAM. Immuno receptor tyrosine based activation motivs Ig G,A,M,D,E Immunoglobulin G,A,M,D,E ILInter leukin $\mathbb{I}P3$ Inisitol triphosphate m Ab Mitogenic antibody MAB Mono clonal antibody **MCV** Mean corpuscular volume MHC Major histo compotibility.

LIST OF ABBREVIATIONS

ANA Antinuclear antibody. Anti-ds Anti-double stranded. APC Antigen presenting cell. APL Anti phospholipid antibody. ARA American Rheumatic Association. BaEV. Babaon endogenous virus. BILAG British international lupus assesment group. CAMP Cyclic adenosin monophosphate. C 1,2,3,4 Complement 1,2,3,4. CD Cluster of differentation. **CCHB** Congenital complete heart block, CHB Complete heart block. C.N.S. Central nervous system. CTLs Cytosolic T-lymphocytes. DAG di-acyl glycerol DNA deoxy riboneuclic acid. DP Douple positive **EBV** Ebestien bar virus **EEG** Electro encephalogram. Enzyme linked immunosorbent assay. **ELLSA** ESR Erythrocyte sedimentation rate. Extractable nuclear antigen. ENA ET-1 Endothelin-1 FANA Fluorescent antinuclear antibody. **GIT** Gastro intestinal tract. Hb Hemoglobin. HIAb Human intercisternal type A retro virus particle. HERVS Human endogenous retro virus. HIV Human immune deficiency virus. Human leukocyte antigen. HLA HTL v-1 Human T-lymphotropic virus. ITAM. Immuno receptor tyrosine based activation motivs Ig G,A,M,D,E Immunoglobulin G,A,M,D,E ILInter leukin $\mathbb{I}P3$ Inisitol triphosphate m Ab Mitogenic antibody MAB Mono clonal antibody **MCV** Mean corpuscular volume MHC Major histo compotibility.

MRI	Magnetic resonanse Image.
MULV	Murine leukemiavirus.
NIA	National institute of health.
NLE	Neonatal lupus erythematosus.
NK	Natural killer
NP	Neuro psycahatric
NSAID	Non stroidal anti-inflamatory drug.
PAN	Poly arteritis nodosa.
PIP2	Phospho inisitol diphosphate
PKC	Phospho kinas C.
PLC γ-1	Phospho lipase C γ 1 enzyme.
PMLE	Polymorpholight eryption.
PTPASE	Protein tyrosine phosphatase.

Partial thrombo palastin lime. Rhevmatoid association nuclear antigen. RANA

Phospho tyrosine kinase.

RES Reticulo endothelial system.

RNP Ribonucleo protein RPRibosomol protein RPR Rapid plasmin reagent. RVT Renal vein thrombosis

SCF Stem cell factor

PTK

PTT

SCIE Subacute cutaneous lupus erythematosus **SGOT** Serum glutamic oxalic trans aminase SGPT Serum glutamic pyruvic transaminase Systemic lupus activity measurement SLAM SLE Systemic lupus erythmematosus

SLEDA SLE disease activity index

SM Smith antibody

SS Ab Single stranded antibody.

TCR T-cell receptor.

TGF Trams forming growth factor,

ThT-helper

TLC Total leukocytic count

T-PBL T-prepheral blood lymphocyte

UΥ Ultraviolet

Venereal disease research laboratory VDRL.

WG Wegeneris granulomatosis. WHO World health organization.

MRI	Magnetic resonanse Image.
MULV	Murine leukemiavirus.
NIA	National institute of health.
NLE	Neonatal lupus erythematosus.
NK	Natural killer
NP	Neuro psycahatric
NSAID	Non stroidal anti-inflamatory drug.
PAN	Poly arteritis nodosa.
PIP2	Phospho inisitol diphosphate
PKC	Phospho kinas C.
PLC γ-1	Phospho lipase C γ 1 enzyme.
PMLE	Polymorpholight eryption.
PTPASE	Protein tyrosine phosphatase.

Partial thrombo palastin lime. Rhevmatoid association nuclear antigen. RANA

Phospho tyrosine kinase.

RES Reticulo endothelial system.

RNP Ribonucleo protein RPRibosomol protein RPR Rapid plasmin reagent. RVT Renal vein thrombosis

SCF Stem cell factor

PTK

PTT

SCIE Subacute cutaneous lupus erythematosus **SGOT** Serum glutamic oxalic trans aminase SGPT Serum glutamic pyruvic transaminase Systemic lupus activity measurement SLAM SLE Systemic lupus erythmematosus

SLEDA SLE disease activity index

SM Smith antibody

SS Ab Single stranded antibody.

TCR T-cell receptor.

TGF Trams forming growth factor,

ThT-helper

TLC Total leukocytic count

T-PBL T-prepheral blood lymphocyte

UΥ Ultraviolet

Venereal disease research laboratory VDRL.

WG Wegeneris granulomatosis. WHO World health organization.

Fig. No.:	List of Figures	Page
Fig. (1):	The T-cell antigen receptor	15
Fig. (2);	Activation of the signaling pathways by TCR	26
Fig. (3):	Role of CD45 in T-cell activation	33
Fig. (4);	Sex distribution among SLE cases	115
Fig. (5):	The mean value of TLC among SLE cases and control group	117
Fig. (6):	The mean value of ESR Ist h among cases and control group.	118
Fig. (7):	The mean value of ESR 2 nd h among cases and control group.	119
Fig. (8):	The mean value of lymphocytic count among SLE cases and control group	121
Fig. (9):	The mean value of absolute CD4 count among SLE and control group	122
Fig. (10):	The mean value of absolute CD8 count amount SLE cases and control	123
Fig. (11):	The mean value of CD45 RA among SLE cases and control	124
Fig. (12);	Detection of CD45 antibody	126

Fig. No.:	List of Figures	Page
Fig. (1):	The T-cell antigen receptor	15
Fig. (2);	Activation of the signaling pathways by TCR	26
Fig. (3):	Role of CD45 in T-cell activation	33
Fig. (4);	Sex distribution among SLE cases	115
Fig. (5):	The mean value of TLC among SLE cases and control group	117
Fig. (6):	The mean value of ESR Ist h among cases and control group.	118
Fig. (7):	The mean value of ESR 2 nd h among cases and control group.	119
Fig. (8):	The mean value of lymphocytic count among SLE cases and control group	121
Fig. (9):	The mean value of absolute CD4 count among SLE and control group	122
Fig. (10):	The mean value of absolute CD8 count amount SLE cases and control	123
Fig. (11):	The mean value of CD45 RA among SLE cases and control	124
Fig. (12);	Detection of CD45 antibody	126

Table No.	LIST OF TABLES	Page
Table (1):	CD45 isoform s	29
Table (2):	Antinuclear antibodeis	39
Table (3);	The 1982 revised criteria	63
Table (4):	Collective laboratory data of SLE patient	111
Table (5):	Collective laboratory data of control group	112
Table (6);	Collective data of clinical presentation in SLE patients	113
Table (7):	Distribution of patients as regard clinical presentation	114
Table (8):	Comparison between SLE patients and control group as regard age	114
Table (9):	Comparison between SLE patients and control group as regard sex	114
Table (10):	Comparison between SLE patients and control group as regard complete hemogram and ESR 1st h and 2nd h.	116
Table (11):	Comparison between SLE patients and control group as regard renal function (urea and createnin)	116
Table (12):	Comparison between SLE patients and control group as regard lymphocytic count, CD4/CD 8, CD4/cd8 ratio and CD45.	120
Table (13):	Comparison between male and female SUE p as CD45 RA %	120
Table (14);	Correlation between CD 45 RA and complete hemogram in SLE patients	120
Table (15):	Correlation between CD 45 RA and ESR 1st h and 2nd h in SLE patients	125
Table (16):	Correlation between CD 45 RA and renal function curea and createnin in SLE patients.	125
Table (17):	Correlation between CD 45 RA and RNA and anti ds DNA in SLE patients.	125
Table (18).	Correlation between CD45 RA and absolute lymphocytic count, CD4, CD8, CD4/ CD8 ratio in SLE patients.	125

ţ,

150

Table No.	LIST OF TABLES	Page
Table (1):	CD45 isoform s	29
Table (2):	Antinuclear antibodeis	39
Table (3);	The 1982 revised criteria	63
Table (4):	Collective laboratory data of SLE patient	111
Table (5):	Collective laboratory data of control group	112
Table (6);	Collective data of clinical presentation in SLE patients	113
Table (7):	Distribution of patients as regard clinical presentation	114
Table (8):	Comparison between SLE patients and control group as regard age	114
Table (9):	Comparison between SLE patients and control group as regard sex	114
Table (10):	Comparison between SLE patients and control group as regard complete hemogram and ESR 1st h and 2nd h.	116
Table (11):	Comparison between SLE patients and control group as regard renal function (urea and createnin)	116
Table (12):	Comparison between SLE patients and control group as regard lymphocytic count, CD4/CD 8, CD4/cd8 ratio and CD45.	120
Table (13):	Comparison between male and female SUE p as CD45 RA %	120
Table (14);	Correlation between CD 45 RA and complete hemogram in SLE patients	120
Table (15):	Correlation between CD 45 RA and ESR 1st h and 2nd h in SLE patients	125
Table (16):	Correlation between CD 45 RA and renal function curea and createnin in SLE patients.	125
Table (17):	Correlation between CD 45 RA and RNA and anti ds DNA in SLE patients.	125
Table (18).	Correlation between CD45 RA and absolute lymphocytic count, CD4, CD8, CD4/ CD8 ratio in SLE patients.	125

ţ,

150